Cargando…

Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies

Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced with the identification of various key oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of person...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajurkar, Swapnil, Mambetsariev, Isa, Pharaon, Rebecca, Leach, Benjamin, Tan, TingTing, Kulkarni, Prakash, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356243/ https://www.ncbi.nlm.nih.gov/pubmed/32549358 http://dx.doi.org/10.3390/jcm9061870

Ejemplares similares

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
por: Pharaon, Rebecca, et al.
Publicado: (2020)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
por: Bosserman, Linda D., et al.
Publicado: (2022)

Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
por: Mambetsariev, Isa, et al.
Publicado: (2022)

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer
por: Won, Brian, et al.
Publicado: (2016)

The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer
por: Hewelt, Blake, et al.
Publicado: (2019)

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
por: Roosan, Moom R., et al.
Publicado: (2021)

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology
por: Mambetsariev, Isa, et al.
Publicado: (2019)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
por: Ramisetty, Sravani, et al.
Publicado: (2023)

Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling
por: Salgia, Ravi, et al.
Publicado: (2020)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
por: Zhao, Dan, et al.
Publicado: (2021)

Clinical Network Systems Biology: Traversing the Cancer Multiverse
por: Mambetsariev, Isa, et al.
Publicado: (2023)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer
por: Mirzapoiazova, Tamara, et al.
Publicado: (2021)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
por: Sattler, Martin, et al.
Publicado: (2023)

Addressing Drug Resistance in Cancer: A Team Medicine Approach
por: Kulkarni, Prakash, et al.
Publicado: (2022)

Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
por: Zarinshenas, Reza, et al.
Publicado: (2023)

Combined Checkpoint Inhibition and Chemotherapy: New Era of 1(st)-Line Treatment for Non-Small-Cell Lung Cancer
por: Wang, Chongkai, et al.
Publicado: (2019)

Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research
por: Subbiah, Shanmuga, et al.
Publicado: (2020)

Integrating Clinical and Translational Research Networks—Building Team Medicine
por: Salgia, Ravi, et al.
Publicado: (2020)

On the Virtues of “Team Medicine”—A City of Hope Perspective
por: Kulkarni, Prakash, et al.
Publicado: (2023)

Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status
por: Chen, Bihong T., et al.
Publicado: (2023)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines
por: Mirzapoiazova, Tamara, et al.
Publicado: (2020)

Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells
por: Mirzapoiazova, Tamara, et al.
Publicado: (2019)

Intrinsically disordered proteins and conformational noise: The hypothesis a decade later
por: Kulkarni, Prakash, et al.
Publicado: (2023)

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2018)

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma
por: Gupta, Rohan, et al.
Publicado: (2019)

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma
por: Wang, Jiale, et al.
Publicado: (2018)

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression
por: Mirzapoiazova, Tamara, et al.
Publicado: (2015)

Biomarkers in immunotherapy: literature review and future directions
por: Pharaon, Rebecca, et al.
Publicado: (2020)

Integration of artificial intelligence in lung cancer: Rise of the machine
por: Ladbury, Colton, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_le9kn17vrbv2ntrd6c1jg136a6